BUZZ-Aeterna Zentaris Inc: To begin late-stage study on hormone drug

Mon Apr 13, 2015 9:56am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian drug developer's U.S.-listed shares up 6 pct at $0.54; Toronto-listed shares up 6.15 pct at C$0.69

** Says plans to conduct confirmatory study on hormone deficiency drug-test after meeting with U.S. Food and Drug Administration

** FDA rejected the test on Nov. 6 last year

** Up to Friday's close, U.S. shares had fallen 60 pct since test was rejected